arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Nuvalent, Inc.

NUVL
$123.97 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuvalent, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.0B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -33.2% ↘
FCF / Share $-3.79 ↘
Trailing P/E —
Price / Book 7.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Jul 14, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-425.38M
↓ -63.1% —
FCF / Share Free cash flow per share
$-3.79
↓ -35.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
21
Cash Quality ↓
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 26 quarters